journal article·2022-05Open access

Biomimetic Immunosuppressive Exosomes that Inhibit Cytokine Storms Contribute to the Alleviation of Sepsis

Yinan Li, Heng Zhang, Caihong Chen, Kailiang Qiao, Zhiyang Li, Jingxia Han, Xu Han, Kun Li, Keguan Lai, Ning Liu, Ang Li, Nannan Xiao, Yan Zhang, Xiangshuai Zhao, Wenqing Gao, Yang Zhang, Huijuan Liu, Tao Sun

Advanced Materials· Volume 34· Issue 19

Abstract

Abstract Sepsis is a disease characterized by multiple organ failure caused by immune hyperactivation and cytokine storms. Studies have shown that the incidence of sepsis in melanoma patients is substantially lower compared to the general population. It is also observed that experimental tumor‐bearing animals have high survival rates after sepsis induction, suggesting that tumors may suppress sepsis‐associated immune overactivation, thereby alleviating sepsis. Based on the above‐described findings, this work assesses whether tumor cells play an antisepsis role in mice through the secretion of exosomes. Analysis of exosome activity reveals that the induced exosomes (iExo) secreted by tumor cells following lipopolysaccharide (LPS) treatment improve sepsis to a greater extent than normal secretory exosomes. Further analysis reveals that iExo exert their protective effects mainly through seven key miRNAs. In vitro bionic simulation of exosomes is carried out using exosome mimics generated by loading the aforementioned microRNAs into hyaluronic acid–polyethylenimine nanoparticles. Exosome mimics at specific miRNA ratios alleviate sepsis in mice and cynomolgus monkeys, indicating that biomimetic simulation of tumor‐suppressive exosomes may represent a promising therapeutic method for the treatment of sepsis and cytokine‐storm‐related conditions.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · MicroRNA in disease regulation · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Medicinal Chemical Biology and College of Pharmacy Nankai University Tianjin 300350 China

Tianjin Key Laboratory of Early Druggability Evaluation of Innovative Drugs and Tianjin Key Laboratory of Molecular Drug Research Tianjin International Joint Academy of Biomedicine Tianjin 300457 China

Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases Tianjin Third Central Hospital Tianjin 300170 China

Department of Anesthesiology Tianjin Fourth Central Hospital Tianjin 300142 China

Funding

China Postdoctoral Science Foundation · Fundamental Research Funds for the Central Universities

References (31)

Show source-provided references
1. 10.1016/S0140-6736(19)32989-710.1016/S0140-6736(19)32989-7 ↗
2. 10.1056/NEJMra120862310.1056/NEJMra1208623 ↗
3. 10.1128/CMR.00046-0810.1128/CMR.00046-08 ↗
4. 10.1016/j.pharmthera.2020.10747610.1016/j.pharmthera.2020.107476 ↗
5. 10.1016/j.jaci.2020.07.00110.1016/j.jaci.2020.07.001 ↗
6. 10.1093/cvr/cvaa07010.1093/cvr/cvaa070 ↗
7. 10.1186/cc289310.1186/cc2893 ↗
8. 10.1371/journal.pone.024344910.1371/journal.pone.0243449 ↗
9. 10.1111/1753-6405.1293510.1111/1753-6405.12935 ↗
10. 10.1038/s41577-019-0264-y10.1038/s41577-019-0264-y ↗
11. 10.15252/emmm.20181012810.15252/emmm.201810128 ↗
12. 10.1038/s41577-021-00541-y10.1038/s41577-021-00541-y ↗
13. 10.1080/2162402X.2015.102747210.1080/2162402X.2015.1027472 ↗
14. 10.4049/jimmunol.100388410.4049/jimmunol.1003884 ↗
15. 10.1016/j.pharmthera.2017.02.02010.1016/j.pharmthera.2017.02.020 ↗
16. 10.1007/s40820-021-00598-310.1007/s40820-021-00598-3 ↗
17. 10.1016/j.freeradbiomed.2021.01.02310.1016/j.freeradbiomed.2021.01.023 ↗
18. 10.1016/j.ymthe.2018.02.02010.1016/j.ymthe.2018.02.020 ↗
19. 10.1161/ATVBAHA.119.31272610.1161/ATVBAHA.119.312726 ↗
20. 10.1016/j.yexcr.2018.08.03010.1016/j.yexcr.2018.08.030 ↗
21. 10.3390/cells906132710.3390/cells9061327 ↗
22. 10.1016/j.arr.2021.10137410.1016/j.arr.2021.101374 ↗
23. 10.4049/jimmunol.080400810.4049/jimmunol.0804008 ↗
24. 10.1016/j.biomaterials.2021.12084510.1016/j.biomaterials.2021.120845 ↗
25. 10.1016/j.molcel.2020.01.02210.1016/j.molcel.2020.01.022 ↗
26. 10.1097/01.CCM.0000128037.72072.2210.1097/01.CCM.0000128037.72072.22 ↗
27. 10.1096/fj.201701536R10.1096/fj.201701536R ↗
28. 10.1002/adhm.20190118210.1002/adhm.201901182 ↗
29. 10.1021/acs.nanolett.8b0068910.1021/acs.nanolett.8b00689 ↗
30. 10.1038/nprot.2008.21410.1038/nprot.2008.214 ↗
31. 10.1074/jbc.M114.58804610.1074/jbc.M114.588046 ↗